- ISSN: 0253-8253
- E-ISSN: 2227-0426
-
oa Can the Central Sympathetic Blockade Profile be Advantageous in the Management of Patients with Metabolic Syndrome?
- Source: Qatar Medical Journal, Volume 2006, Issue 2, نوفمبر ٢٠٠٦, 6
-
- ٠١ نوفمبر ٢٠٠٦
ملخص
Metabolic syndrome, the association of obesity, hypertension and hyperlipidaemia in conjunction with impaired glucose tolerance or frank diabetes, is a rising global pattern and has been subjected to a useful consensus re-definition in recent months. Its origins are fixed in changing dietary and activity patterns across the developed world but also increasingly affecting all developing economies. The obvious sequelae of this spiraling pattern are increases of atherosclerotic vascular disease and subsequent occlusive vascular events, morbidity and premature mortality for affected patients. Given its emerging importance we should consider carefully the role of the sympathetic nervous system in the overlapping management of the pathophysiology of obesity and hypertensive vascular disease; the recognition of the metabolic syndrome and its definition in practice; and whether new trial results pertinent to managing hypertension in the overweight patient with metabolic syndrome using the central imidazoline antagonist drug, moxonidine, might prompt reconsideration of this established strategy for lowering blood pressure.
